LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

Начало・Списък с акции・Beam Therapeutics Inc

Beam Therapeutics Inc

Затворен

СекторЗдравеопазване

31.74 -1.76

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

31.64

Максимум

34.27

Ключови измерители
By Trading Economics
Приходи	357M 244M
Продажби	104M 114M
Марж на печалбата	214.091
Служители	511
EBITDA	368M 261M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+54.7% upside

Дивиденти
By Dow Jones
Следващи печалби	4.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	216M 3.1B
Предишно отваряне	33.5
Предишно затваряне	31.74

Настроения в новините

By Acuity

21%

79%

57 / 346 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

16.225 / 20.17 Подкрепа & съпротива

Beam Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

11.05.2026 г., 22:15 ч. UTC

Придобивния, сливания и поглъщания

BMO Financial Group to Sell Transportation-, Vendor-Finance Businesses to Stonepeak

11.05.2026 г., 23:46 ч. UTC

Пазарно говорене

Yen Consolidates as Traders Await Bessent's Meetings -- Market Talk

11.05.2026 г., 23:44 ч. UTC

Пазарно говорене

Nikkei May Rise on AI Enthusiasm -- Market Talk

11.05.2026 г., 23:33 ч. UTC

Пазарно говорене

Gold Rises on Possible Position Adjustments -- Market Talk

11.05.2026 г., 22:37 ч. UTC

Пазарно говорене

CSL's Profit, Revenue Downgrade 'Not a Complete Surprise' -- Market Talk

11.05.2026 г., 22:32 ч. UTC

Печалби

Verde Clean Fuels 1Q Loss/Shr 5c >VGAS

11.05.2026 г., 22:02 ч. UTC

Пазарно говорене

Значими събития в новините

Stellar Auto Sales Increase in Canada Could Be Tied to Return of EV Incentives -- Market Talk

11.05.2026 г., 21:49 ч. UTC

Печалби

Rigetti Computing Revenue Triples. Why the Quantum Stock Is Falling. -- Barrons.com

11.05.2026 г., 21:42 ч. UTC

Пазарно говорене

Declining Hours Worked Should Keep Bank of Canada Firmly on Hold -- Market Talk

11.05.2026 г., 21:32 ч. UTC

Придобивния, сливания и поглъщания

Bank of Montreal to Sell Transportation Finance and Vendor Finance Businesses to Stonepeak

11.05.2026 г., 21:32 ч. UTC

Придобивния, сливания и поглъщания

BMO: Supports Strategy to Elevate Returns and Accelerate Growth, Transaction Accretive to Cap Ratios and ROE >BMO.T

11.05.2026 г., 21:32 ч. UTC

Придобивния, сливания и поглъщания

BMO: Positions Businesses for Continued Growth in Efficient Cap Structure >BMO.T

11.05.2026 г., 21:32 ч. UTC

Придобивния, сливания и поглъщания

BMO: To Invest in 19.9% Equity Interest, Enabling Continued Participation in the Businesses' Long-Term Value Creation >BMO.T

11.05.2026 г., 21:31 ч. UTC

Придобивния, сливания и поглъщания

BMO: Announces Strategic Sale of Transportation and Vendor Finance Businesses

11.05.2026 г., 21:23 ч. UTC

Придобивния, сливания и поглъщания

CSG Systems Sale to NEC Gets CFIUS Clearance

11.05.2026 г., 21:12 ч. UTC

Печалби

Ovintiv: Full-Yr Production Volumes Expected to Avg 620 to 645 MBOE/d, Full-Yr Expected Cap Investment of $2.25B to $2.35B >OVV

11.05.2026 г., 21:12 ч. UTC

Печалби

Ovintiv 1Q Loss/Shr $2.35 >OVV

11.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

11.05.2026 г., 20:44 ч. UTC

Печалби

Steris: Board Approves New $1B Shr Repurchase Program >STE

11.05.2026 г., 20:43 ч. UTC

Печалби

Whirlpool Shares Are Still Falling. Last Week's Earnings Might Be Why. -- Barrons.com

11.05.2026 г., 20:32 ч. UTC

Печалби

CleanSpark 2Q Loss/Shr $1.52 >CLSK

11.05.2026 г., 20:32 ч. UTC

Печалби

CleanSpark 2Q Rev $136.4M >CLSK

11.05.2026 г., 20:30 ч. UTC

Печалби

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

11.05.2026 г., 20:30 ч. UTC

Печалби

Steris 4Q Cont Ops EPS $2.24 >STE

11.05.2026 г., 20:30 ч. UTC

Печалби

Steris 4Q Rev $1.6B >STE

11.05.2026 г., 20:30 ч. UTC

Печалби

Steris Sees FY Adj EPS $11.10-Adj EPS $11.30 >STE

11.05.2026 г., 20:30 ч. UTC

Печалби

Steris 4Q Adj EPS $2.83 >STE

11.05.2026 г., 20:22 ч. UTC

Горещи акции

Stocks to Watch: Moderna, Intel, Micron, Fox -- WSJ

11.05.2026 г., 19:37 ч. UTC

Печалби

More Bad News at KKR's Private Credit Fund -- Barrons.com

11.05.2026 г., 19:32 ч. UTC

Пазарно говорене

Oil Gains As Trump Rejects Iran's Response to U.S. Plan -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Beam Therapeutics Inc Прогноза

Ценова цел

By TipRanks

54.7% нагоре

12-месечна прогноза

Среден 50 USD 54.7%

Висок 80 USD

Нисък 26 USD

Според 12 анализатори от Wall Street, предложили 12-месечна ценова цел за Beam Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

12 ratings

Купи

Задържане

Продай

Според 12 анализатори, дали борсови рейтинги на Beam Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

16.225 / 20.17Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bearish.

Настроение

By Acuity

57 / 346 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Beam Therapeutics Inc

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.